The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
Open accessAbstract
BACKGROUND: Data from multiple sclerosis (MS) and the MS rodent model, experimental autoimmune encephalomyelitis (EAE), highlighted an inflammation-dependent synaptopathy at the basis of the neurodegenerative damage causing irreversible disability in these disorders. This synaptopathy is characterized by an imbalance between glutamatergic and GABAergic transmission and has been proposed to be a potential therapeutic target. Siponimod (BAF312), a selective sphingosine 1-phosphate1,5 receptor modulator, is currently under investigation in a clinical trial in secondary progressive MS patients. We investigated whether siponimod, in addition to its peripheral immune modulation, may exert direct neuroprotective effects in the central nervous system (CNS) of mice with chronic progressive EAE. METHODS: Minipumps allowing continuous intracerebroventricular (icv) infusion of siponimod for 4 weeks were implanted into C57BL/6 mice subjected to MOG35-55-induced EAE. Electrophysiology, immunohistochemistry, western blot, qPCR experiments, and peripheral lymphocyte counts were performed. In addition, the effect of siponimod on activated microglia was assessed in vitro to confirm the direct effect of the drug on CNS-resident immune cells. RESULTS: Siponimod administration (0.45 μg/day) induced a significant beneficial effect on EAE clinical scores with minimal effect on peripheral lymphocyte counts. Siponimod rescued defective GABAergic transmission in the striatum of EAE, without correcting the EAE-induced alterations of glutamatergic transmission. We observed a significant attenuation of astrogliosis and microgliosis together with reduced lymphocyte infiltration in the striatum of EAE mice treated with siponimod. Interestingly, siponimod reduced the release of IL-6 and RANTES from activated microglial cells in vitro, which might explain the reduced lymphocyte infiltration. Furthermore, the loss of parvalbumin-positive (PV+) GABAergic interneurons typical of EAE brains was rescued by siponimod treatment, providing a plausible explanation of the selective effects of this drug on inhibitory synaptic transmission. CONCLUSIONS: Altogether, our results show that siponimod has neuroprotective effects in the CNS of EAE mice, which are likely independent of its peripheral immune effect, suggesting that this drug could be effective in limiting neurodegenerative pathological processes in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool
Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M., & Rossi, F. M. V. (2011) · Nature Neuroscience · doi:10.1038/nn.2887 · Cited by 1,061 · cited 1×
“Microglia activation occurs early in the EAE brain and spinal cord, before the appearance of motor deficits [25, 39, 40].”
BackgroundGDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820 · cited 1×
“Further studies are needed to dissect the mechanisms of neuroprotection exerted by siponimod on PV+ interneurons: other mechanisms involving neuroprotective factors, like the brain-derived neurotrophic factor (BDNF), may be implied [51].”
BackgroundInhibitory role for GABA in autoimmune inflammation
Bhat, R., Axtell, R., Mitra, A., Miranda, M., Lock, C., Tsien, R. W., & Steinman, L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915139107 · Cited by 509
Exploring the origins of grey matter damage in multiple sclerosis
Calabrese, M., Magliozzi, R., Ciccarelli, O., Geurts, J. J. G., Reynolds, R., & Martin, R. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3900 · Cited by 414 · cited 4×
“Clinically, two main forms of MS can be distinguished, the relapsing-remitting (RRMS) and the progressive, where the latter is described as the gradual progression of clinical disability in a patient either with a preceding relapsing course (secondary progressive MS (SPMS)) or without a preceding relapsing course (pri…”
BackgroundInfluentialCentonze, D., Muzio, L., Rossi, S., Cavasinni, F., De Chiara, V., Bergami, A., Musella, A., D'Amelio, M., Cavallucci, V., Martorana, A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5804-08.2009 · Cited by 390 · cited 4×
“We have recently demonstrated that inflammation causes an imbalance between the glutamatergic and the GABAergic transmission in the EAE striatum [6, 15].”
BackgroundMethodInfluentialSelf-citationThe place of dopamine in the cortico-basal ganglia circuit
Haber, S. N. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.008 · Cited by 364 · cited 1×
“Interestingly, in our study, the attenuation of the motor symptoms of EAE mice treated with siponimod was observed in the symptomatic phase of the disease in connection to the improved tone of the GABAergic transmission in the striatum, a subcortical brain area involved in motor control [53] and compromised in MS [54].”
BackgroundCzeh, B., Simon, M., van der Hart, M. G., Schmelting, B., Hesselink, M. B., & Fuchs, E. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300581 · Cited by 136 · cited 1×
“Inflammation is thought to play a role in this neuronal death, which has been observed in other brain inflammatory conditions [49] and in rodent chronic stress paradigms [50].”
BackgroundImpaired striatal GABA transmission in experimental autoimmune encephalomyelitis
Rossi, S., Muzio, L., De Chiara, V., Grasselli, G., Musella, A., Musumeci, G., Mandolesi, G., De Ceglia, R., Maida, S., Biffi, E., et al. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.004 · Cited by 112 · cited 7×
“Mice were killed by cervical dislocation, and corticostriatal coronal slices (200 μm) were prepared from fresh tissue blocks of the brain with the use of a vibratome [6, 15].”
BackgroundMethodInfluentialSelf-citation
Cited by
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Self-citationCohen, J. A., Comi, G., Selmaj, K. W., Bar-Or, A., Arnold, D. L., Steinman, L., Hartung, H.-P., Montalban, X., Kubala Havrdová, E., Cree, B. A. C., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30238-8 · Cited by 279
Microglia in multiple sclerosis: protectors turn destroyers
Yong, V. W. (2022) · Neuron · doi:10.1016/j.neuron.2022.06.023 · Cited by 185
Colombo, E., Bassani, C., De Angelis, A., Ruffini, F., Ottoboni, L., Comi, G., Martino, G., & Farina, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00635 · Cited by 66
“In vivo findings from experimental neuroinflammation support the hypothesis of protective effects of BAF312 in the CNS (33).”
BackgroundInfluentialRemyelination in Multiple Sclerosis: Findings in the Cuprizone Model
Leo, H., & Kipp, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416093 · Cited by 46
Metadata
- Authors
- Gentile, A., Musella, A., Bullitta, S., Fresegna, D., De Vito, F., Fantozzi, R., Piras, E., Gargano, F., Borsellino, G., Battistini, L., Schubart, A., Mandolesi, G., & Centonze, D.
- Venue
- Journal of Neuroinflammation
- Published
- 2016-08-26
- Volume
- 13
- Issue
- 1
- Pages
- 207-207
- ISSN
- 1742-2094 (ISSN-L)
- OpenAlex
- W2517566610
- Cited by
- 159
- References
- 9
- FWCI
- 9.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. https://app.cochat.ai/papers/10.1186/s12974-016-0686-4
- The paper
- Gentile, A., Musella, A., Bullitta, S., Fresegna, D., De Vito, F., Fantozzi, R., Piras, E., Gargano, F., Borsellino, G., Battistini, L., Schubart, A., Mandolesi, G., & Centonze, D. (2016). Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-016-0686-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.